They found that the proximal PolyA selection of CARM1, through loss of miRNA binding, upregulates CARM1's EMT inducers and releases miRNAs that downregulate the EMT inhibitor RBM47, serving as a pathological biomarker for mesenchymal tumours and tumour metastasis. This evidence concerns the gene CARM1 and mesenchymal cell neoplasm.